Gefitinib for refractory advanced non-small-cell lung cancer [6]

Lancet

Volumn 367, Issue 9507, 2006, Pages 300-

  Tsurutani, Junji ^a   Ballas, Marc ^a   Steinberg, Seth M ^a   Egilsson, Valgardur ^b   Dennis, Phillip A ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b LANDSPITALI UNIVERSITY HOSPITAL   (Iceland)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR KINASE; ERLOTINIB; GEFITINIB;

ADENOCARCINOMA; CANCER SURVIVAL; DRUG EFFICACY; HUMAN; LETTER; LUNG ALVEOLUS CELL CARCINOMA; LUNG NON SMALL CELL CANCER; PRIORITY JOURNAL; SMOKING;

EID: 31444445239     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(06)68064-1     Document Type: Letter

References (4)

1. N Thatcher, A Chang, P Parikh Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer) Lancet 366 2005 1527 1537
2. FA Shepherd, J Rodrigues Pereira, T Ciuleanu Erlotinib in previously treated non-small-cell lung cancer N Engl J Med 353 2005 123 132
3. MS Tsao, A Sakurada, JC Cutz Erlotinib in lung cancer - molecular and clinical predictors of outcome N Engl J Med 353 2005 133 144
4. OS Breathnach, N Ishibe, J Williams Clinical features of patients with stage IIIB and IV bronchioloalveolar carcinoma of the lung Cancer 86 1999 1165 1173